Wednesday, January 31, 2018 The MAP3 trial is considered permanently closed. MAP3 is a Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer. For further information please contact Christine Bertrim
